Drug Approval | February 20, 2023
Briefs: Neuland Laboratories, Cipla and Zydus
Cipla has received 8 inspectional observations in Form 483
Cipla has received 8 inspectional observations in Form 483
There is a fast resurgence in the transplant activities post COVID
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Themis will market this drug with the brand name REMITHEM.
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
